It's not often that medical convention audiences clap in the middle of a presentation.
Yet this is what happened last week at the International Cancer Congress (Esmo) in Paris.
Researcher Myriam Chalabi, from the Netherlands Cancer Institute in Amsterdam, presented the results of a phase III trial (the most relevant for deciding on the usefulness of a treatment) on the interest of immunotherapy before surgery in a particular subtype of colorectal cancer patients.
“Innovative”, “exceptional”
, the dithyrambic qualifiers of the commentators are not so frequently used as that in oncology.
The patients concerned have a very genetically unstable tumour, called MSI, for microsatellite instability.
This anomaly is routinely detected using a test during the diagnostic biopsy (performed on a piece of tumor removed during surgery).
It is present in 10% to 15% of patients with…
This article is for subscribers only.
You have 72% left to discover.
Pushing back the limits of science is also freedom.
Keep reading your article for €0.99 for the first month
I ENJOY IT
Already subscribed?
Login
